A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SDN -037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.
Latest Information Update: 19 May 2021
At a glance
- Drugs Difluprednate (Primary)
 - Indications Ocular inflammation; Ocular pain
 - Focus Registrational; Therapeutic Use
 - Sponsors Sun Pharma Advanced Research Company
 
Most Recent Events
- 21 Oct 2020 New trial record
 - 14 Oct 2020 Primary endpoint has been met. (proportion of subjects with an anterior chamber cell grade of 0 at Day 15), according to a China Medical System media release.
 - 14 Oct 2020 Results presented in a China Medical System media release.